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1. Introduction 
1.1 Musculoskeletal disorders (MSDs) 
The Musculoskeletal or locomotor system is defined by a complex interconnection of 
different body parts functionally arranged in two main sub-systems: the skeletal system, 
composed of the bones, and secondly the muscle system. In addition other structures such 
as tendons, ligaments and other connective tissue joins both sub-systems providing 
functional and structural support.  
Musculoskeletal disorder or more generically Rheumatic disease (RD) is a term used to describe 
over 200 different disorders involving different connective tissue. Depending on the main target 
affected, RDs can be grouped into different pathologies. Joints are structures commonly affected 
in RDs, as it is the location where bone, tendon, ligament and muscle meet. Joint disorders are 
generically termed as arthropathies, and it is only when inflammation occurs, in one or more 
joints, that the disorder is called arthritis. However, RDs also include systemic disorders 
(autoimmune diseases affecting multiple organs), dorsopathies (back disorders), soft tissue 
disorders (involving muscles, tendons, etc.), and osteopathies/chondropathies (e.g., disorders 
related to bone density and structure-like osteoporosis). 
The prevalence of RDs in the elderly has erroneously been associated only with ageing; 
however RDs may develop at any time even in childhood (Manners, 2003, Mariller, 2005). 
Musculoskeletal disorders constitute the most common cause of severe chronic pain and 
physical disability, thus they are considered a public health problem that affect millions of 
individuals and constitute a major burden on health care, a situation which is aggravated by 
an increasingly aging population (Bansback, 2005, Loza, 2008). 
1.2 Aetiology of osteoarthritis  
Osteoarthritis is the most prevalent type of inflammatory arthritis (Spahn, 2011). Although it 
has long been considered to be primarily a cartilage disorder, induced by accumulated 
mechanical stress, as occurs in many other arthropathies the contribution of an 
inflammatory component is well established; sometimes produced by an autoimmune 
response, leading to chronic joint inflammation, destruction and cartilage loss. Little is 
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known about underlying molecular mechanisms. Its initiation and progression appear to be 
independent processes associated with different risk factors (Worthington, 2005). In 
addition to biomechanical stress on articular cartilage, the involvement of other tissues of 
the affected joint, such as the synovium, ligaments, periarticular muscles, and nerves, have 
also been proposed in OA aetiology and progression (Brandt, 2006). Several studies suggest 
that the subchondral bone is likely to be the most important structural element in both pain 
generation and disease progression. At least in its generalised form, OA shows features of a 
systemic musculoskeletal disease with a metabolic component and a genetic predisposition 
leading to the formation of a defective cartilage matrix (Aspden, 2008, Zhu, 2009). 
Unfortunately, despite advances in research, little is known about OA’s exact etiology and 
pathogenetic mechanisms. 
Currently there is no known cure for OA, and modern treatments only manage to reduce pain 
and maintain joint movement as much as possible. For many years the only known options for 
OA treatment were disease-modifying drugs, in mild cases, and several types of surgery 
depending on the affectation of articular structures. Among the surgery choices, arthroscopy 
and joint arthroplasty are the most common. The first is used in people with moderate lesions 
of articular cartilage or bone, in order to alleviate pain for a short time and to allow the joints 
to move more easily. Although it does not seem to treat the arthritis itself, sometimes the relief 
can delay the use of other more aggressive surgeries (Laupattarakasem, 2008). Total or partial 
joint arthroplasty is the ultimate surgical treatment when joint damage can be seen on 
radiographs. It involves surgery to replace the ends of bones, mostly in the hip, knee and 
shoulder thereby creating new surfaces. However, surgery is not recommended in those cases 
where the patient's health is precarious, due to serious risk of infections, and because after 
surgery, long periods of physical rehabilitation are needed. Moreover, the prostheses have a 
lifespan of 10 to 20 years, after which they require substitution. 
In this therapeutic context, it is easy to understand that there is a real and urgent need for 
new and alternative treatments to circumvent the relatively low efficiency of existing 
therapies. This is where the emerging potential of regenerative medicine becomes 
increasingly important as the most promising method to restore, maintain or improve tissue 
structure and joint function (Bruder, 1997, Mackay, 1998, Pittenger, 1999, Zavan, 2007). 
2. Regenerative medicine in rheumatic diseases 
Broadly speaking, the term “regenerative medicine” refers to a new field in biomedical 
research focused on the development of therapeutic approaches allowing the body to 
replace and regenerate damaged or diseased cells, and ultimately the function of tissues and 
organs. This goal is achieved by means of a combination of approaches that include the use 
of soluble molecules, biomaterials, tissue engineering, gene therapy, stem cell 
transplantation and the reprogramming of cell and tissue types. 
In the context of musculoskeletal disease, and in particular the reconstruction of articular 
defects caused by trauma or disease, the goal is to deliver cells that become competent in the 
defect site, initially optimizing biomechanics, and ultimately initiating new tissue 
production. Sometimes, as occurs in the case of soft tissue repair, an additional implant 
vehicle(s), is required to transport and constrain the implanted cells in the defect site and to 
provide mechanical stability to the surgical site. The progressive biodegradation of the 
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vehicle during new tissue formation would be the optimal scenario for the repairing 
process. However, this seemingly straightforward schema can be complicated depending on 
the tissue to repair, which in turn determines not only the type of cells to use but also the 
number and the mode of application. Thus, current challenges in musculoskeletal 
regenerative medicine cover several topics under study including: (1) the better 
understanding of cell biology,  (2) the synthesis of new biomaterials for extracellular 
matrices (scaffolds), and (3) the definition of the best combination of cells, biologically active 
molecules and vehicles to promote growth and differentiation. 
2.1 Regenerative medicine using mature chondrocytes 
Given that cells are the main building blocks of regenerative therapies, their availability and 
their commitment to a specific lineage are major limitations. The cells can be of autologous 
(host-derived) or allogeneic origin (non-host derived). Other sources, are cells of xenogeneic 
(from individuals of another species), syngeneic or isogeneic (isolated from genetically 
identical organisms or highly inbred individuals, respectively) origin are only constrained to 
experimental models. 
Obviously, the most logical approach for the regeneration of joint degraded cartilage, 
consists in the direct re-establishment of its main functional component, the chondrocytes. 
Joint cartilage is a connective tissue with special characteristics. It consists of chondrocytes 
that secrete a cartilage-specific extracellular matrix (ECM) made of collagens, mainly type II 
collagen, and different proteoglycans. The chondrocytes do not have direct cell-to-cell 
contact, thus each cell acts as a functional unit responsible for the production and 
maintenance of the ECM in its surrounding. These characteristics, in addition to the cartilage 
avascularity, explain the difficulties involved in repairing this tissue, because 
chondroprogenitor cell access to the damaged site is very limited. 
The first approach, and the gold standard for years in joint orthopaedic surgery, has been 
the autologous chondrocyte implantation (ACI), after harvesting, from healthy cartilage 
biopsies and expanded in culture.  So far, thousands of ACIs have been clinically applied 
with encouraging results in the short- and mid-term, but their long-term efficiency needs 
further confirmation (Alvarez-Dolado, 2007). The effectiveness of the technique is limited by 
some major drawbacks, including the absence of appropriate sources of suitable hyaline 
cartilage and the additional damage caused at the site of biopsy. Other important issues 
arise during chondrocyte expansion in vitro and further transplantation.  In culture, 
chondrocytes easily dedifferentiate losing their chondrogenic phenotype and their re-
differentiation potential and once it occurs, about half of the ACIs show evidence of 
chondrocyte hypertrophy, indicating the formation of a bone-like tissue. Finally, the 
occurrence of poor adhesion between the new and the original tissue is common and in 
those cases where scaffolds are used, the biomechanical properties obtained do not achieve 
the expected results. These problems have raised the need for alternative cell sources with 
chondrogenic potential for cartilage tissue engineering, a requisite accomplished by the stem 
cells, and in particular by mesenchymal stem cells (MSCs). 
2.2 Regenerative medicine using MSCs 
Under normal conditions body tissues are subjected to a continuous process of repair and 
regeneration of damaged and dead cells by means of a pool of progenitor or stem cells, 
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which have the capacity to differentiate into the specialised cell type being replaced. ‘Stem 
cells’ is a generic term to describe a variety of cells which share two common characteristics: 
(1) their self-renewal potential and (2) their capacity to give rise to different tissues. 
However their “potency”, or differentiation potential is variable and therefore there exists a 
hierarchy according to stem cell types. The most versatile, the totipotent embryonic stem 
cells (ESCs) give rise to other embryonic or extra embryonic adult stem cells (ASCs) with 
pluri- multi- or uni- potentiality. Pluripotent stem cells are descendants of totipotent cells 
and can differentiate into cells derived from the endoderm, mesoderm and ectoderm germ 
layers. Multipotent stem cells can produce only cells of a closely related family of cells, e.g., 
hematopoietic stem cells and MSCs. Finally, unipotent cells only produce one cell type, but 
retain their self-renewal properties, a feature that distinguishes them from other non-stem 
cells. 
 
Fig. 1. Diagram of the mesenchymal stem cell lineage and its differentiation potential 
MSCs have the potential to differentiate into several cell types of mesodermal origin 
including bone, cartilage, muscle, bone marrow stroma, tendon/ligament, fat, dermis. Thus 
these cells are optimal candidates in regenerative medicine strategies intended to restore 
these connective tissues. Adapted from (Caplan, 2007). 
Although for the purposes of regenerative medicine, ESCs could be considered the optimal 
candidates; their clinical use in human therapies is still controversial due to ethical issues. In 
the context of musculoskeletal diseases, the least compromised are mesenchymal stem cells 
(MSCs) and are of particular interest for several reasons. First, they are the progenitors of 
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cells giving rise to a variety of cells which can form connective tissues such as chondrocytes, 
osteocytes, adipocytes and tenocytes (Pittenger, 1999), (Figure 1) and second: in contrast to 
most other adult stem cells, they can be isolated from a diversity of accessible tissues, such 
as bone marrow, fat tissues and umbilical cord blood (Chanda, 2010, Moretti, 2010, 
Romanov, 2005). Moreover, they can be isolated and identified through their adhesion 
potential in culture and by the expression of several “positive markers”, represented by the 
transmembrane proteins CD90, CD73, CD105 and CD166. Additionally, MSCs are easily 
expanded in vitro without losing their “stemness” and/or self-renewal capacity (Bianco, 
2001, Caplan, 2000, Reiser, 2005). 
MSCs have been shown to differentiate in vitro into bone, cartilage, muscle, tendon, and 
fat, and possibly also into cardiomyocytes and hepatocytes (Conget, 1999, Chivu, 2009, 
Dennis, 1999, Pereira, 1995, Pittenger, 1999, Remy-Martin, 1999). Finally, from an 
immunological point of view, an important property of MSCs, especially for their use in 
rheumatic diseases, resides in their potent immunosuppressive and anti-inflammatory 
functions, the lack of induction of graft rejection and their chemotactic properties, similar 
to immune cells in response to injury on sites of inflammation (Le Blanc, 2004, Spaeth, 
2008). As such, these cells are currently being considered for their potential use in cell and 
gene therapy, in a large number of human diseases, and particularly in a variety of clinical 
musculoskeletal conditions, including the repair of cartilage defects, tendon/ligament and 
bone.  
2.3 MSCs and cartilage repair in OA 
As occurs during embryogenesis, the generation of new cartilage (chondrogenesis) involves 
the MSCs progression through different stages in a tightly regulated process coordinated by 
multiple signalling pathways which include the Wnt, Notch or TGF (Quintana, 2009, Roelen, 
2003). In particular, the Wnt/β-catenin signalling pathway plays a crucial role in cartilage 
reparation, since it participates in the differentiation of MSCs into osteoblasts or 
chondrocytes during osteogenesis and/or chondrogenesis (Day, 2005, Gaur, 2005, Hill, 
2005). Markedly, alteration in any of the aforementioned pathways, as occurs in some 
diseases, can lead to detrimental effects during the regeneration process. 
In vitro chondrogenesis is routinely performed by culturing MSCs in three dimensional 
scaffolds made of different biomaterials such as collagen, fibrin, agarose, alginate, chitosan 
or hyaluronic acid of natural or synthetic origin, or a combination of both types (Li, 2005, 
Lisignoli, 2005, Necas, 2010, Zhou, 2008).  In addition, these scaffolds can be supplemented 
with soluble factors such as TGF-β, growth factors, bone morphogenetic proteins (BMPs), 
etc. to facilitate the chondrogenic differentiation of MSCs. 
Application of engineered MSCs for cartilage regeneration has been addressed by the slight 
modifications of two main approaches widely tested in different OA animal models with 
encouraging results (Figure 2).  
In the first, MSCs are seeded on 3D scaffolds with the presence or  absence of soluble factors 
(growth factors and/or cytokines) and the resulting structure is used to repair the cartilage 
defect (Zscharnack, 2010). The second approach, consists of the direct administration of 
MSCs, (loaded or not in 3D scaffolds) without previous differentiation (Thorpe, 2010).  
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Fig. 2. MSC-based tissue engineering and cell therapy for cartilage repair and regeneration. 
Once MSCs are isolated and expanded, both tissue engineering and cell therapy approaches 
are suited for regeneration. In the ex vivo approach cells are loaded in vitro onto the scaffolds 
under appropriate stimuli and after a short incubation to insure attachment, the cell-scaffold 
composites are implanted. Another strategy is based on local injection into the affected joint. 
Adapted from (Caplan, 2007). 
www.intechopen.com
 
Therapeutic Potential of MSCs in Musculoskeletal Diseases (Osteoarthritis) 
 
267 
However, there are still some unanswered questions about the mechanism by which MSCs 
perform the repair; but several possibilities have been outlined, such as the following: (1) the 
secretion of cytokines to enhance repair (Chen, 2008); (2) the modulation of immune 
(Aggarwal, 2005, Gerdoni, 2007, Karussis, 2008, Le Blanc, 2007, Ren, 2008) and inflammatory 
responses (Gupta, 2007, Ortiz, 2007); (3) stimulation of the proliferation of tissue 
endogenous stem cells (Lee, 2006, Munoz, 2005); and (4) the rescue of damaged cells (Spees, 
2006, Spees, 2003). Finally, MSCs are the subject in a controversy where their contradictory 
effects in vitro and in vivo on tumour cell growth have been called into question. Recent 
studies have shown that MSCs can increase the proliferation of tumor cells in vitro and 
promote tumor growth in vivo by increasing the neovascularization (Suzuki, 2011, Tian, 
2011). This is a major concern that should be carefully considered, particularly in conditions 
where tumoral malignancies are present. 
3. Studies carried out in our group 
Our group has been focused for several years on the study of the biology of articular 
cartilage in the OA pathogenesis and the potential of MSCs in regeneration of damaged 
cartilage due to this disease. Some of the issues addressed include the basic research and the 
clinical trials to validate the translational efficacy in the clinic of MSC implantation. Much of 
our work in this field has been based on the use of modern techniques, that include 
proteomics and genomics approaches in combination with bioinformatics and genetic 
validation. 
Proteomics is considered and emerging field with widespread potential applications to 
shape how rheumatic diseases are diagnosed, prognosticated, and clinically managed 
(Camafeita, 2009, Vanarsa, 2010). A key methodological advance in the classical two-
dimensional gel electrophoresis (2-DE) has been the emergence of multiplexing two-
dimensional fluorescence difference gel electrophoresis (2D-DIGE) (Unlu, 1997). The 2D-
DIGE technique circumvents many of the issues associated with traditional 2-DE, providing 
more sensitivity, high reproducibility and a wide dynamic range of detection (Alban, 2003, 
Viswanathan, 2006). It consists in the labelling of lysine groups on protein extracts with 
fluorescent dyes with different emission spectra before isoelectric focusing (IEF). Protein 
samples are further labelled with Cy3 and Cy5 fluorescent dyes, while Cy2 dye is used to 
label the internal standard, which consists of a pooled sample comprising equal amounts of 
all samples to be compared. Then the three samples are electrophoresed on a single 2D gel, 
which allows both direct quantitative comparisons within each gel and the normalization of 
quantitative abundance values for each protein between gels. The combination of 2D-DIGE 
with matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-
TOF MS) provides a powerful tool for identifying disease-related proteins (Stults, 2005). 
(Figure 3). Genomic approaches have been developed through DNA microarray analysis, a 
proven “state of the art” technology for the simultaneous screening of expression levels in 
large numbers of genes (Licatalosi, 2010). (Figure 4) 
Another strategy, different from the previous two, is the systemic application of MSCs, that 
have been shown to promote tissue repair by formation of fibrocartilage-like tissues in 
response to damaged subchondral bone (Chang, 2011), which is likely due to the intrinsic 
ability of MSCs to migrate into injured or inflamed tissues. 
www.intechopen.com
 
Tissue Regeneration – From Basic Biology to Clinical Application 
 
268 
 
Fig. 3. Schematic representation of the 2D-DIGE methodology  
2D-DIGE used for the analysis of protein differential expression in MSCs and chondrocytes 
of patients with osteoarthritis (sample A) compared to control subjects (sample B). CHAPS, 
3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate; Em, Emission; Ex, 
Excitation; IEF, isoelectrofocusing. MM, Molecular mass; pI, Isoelectric point; SDS PAGE, 
polyacrylamide gel electrophoresis in the presence of Sodium Dodecyl Sulphate. 
www.intechopen.com
 
Therapeutic Potential of MSCs in Musculoskeletal Diseases (Osteoarthritis) 
 
269 
 
Fig. 4. Schematic representation of the DNA microarray methodology.  
DNA microarrays are commonly used to detect messenger RNAs (mRNA), referred to as 
expression profiling. The method consists in the fluorescently labelling of RNA while the RNA 
is converted into complementary DNA (cDNA). Amplification of sequences by PCR is 
sometimes incorporated into this step. Two-color labeling allows two samples or conditions, to 
be hybridized to the same array and their gene expression profiles compared via the difference 
in the fluorescence of the two samples. Statistical post-processing of the fluorescence data is 
usually necessary to eliminate artifacts and false results from the data obtained. 
3.1 Proteomic studies in Chondrocytes and MSCs in osteoarthritis 
The breakdown of cartilage in OA involves the degradation of the extracellular matrix 
macromolecules and the altered expression of chondrocyte proteins necessary for normal 
joint function (Lane Smith, 2000). Thus the screening of proteins with altered expression in 
chondrocytes from patients with end stage OA compared to control subjects could expand 
the knowledge of the pathological processes implicated in the damage of articular cartilage 
in OA. Elucidation of the phenotypical alterations occurring in OA is important for the 
ascertainment of disease aetiology and for the development of effective treatments for OA. 
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Fig. 5. Gene ontology annotation of the 27 changed proteins identified in OA chondrocytes. 
Our first proteomic study dates from 2008 (Rollin, 2008c). Here human knee cartilage was 
obtained during total joint replacement surgery in six patients with clinical and radiological 
features of OA and six control samples from adult donors of similar age. Chondrocytes were 
isolated and cultured during 2-3 weeks at confluence in primary culture, before protein 
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extraction. After 2D-DIGE, differentially expressed proteins were excised from the gel, 
digested with trypsin and analysed by a MALDI-TOF MS mass spectrometer. Protein 
identification after peptide mass fingerprinting (PMF) enabled the identification of 27 
proteins (14 decreased and 13 increased) in OA chondrocytes. The cellular localization, 
biological process and molecular functions and of the identified proteins obtained from the 
online FatiGO ontology database are summarized in (Figure 5).  
In this study, a significant differential expression pattern was observed for 27 different 
chondrocyte proteins. These included an elevated number of cytoskeletal binding proteins 
cytoskeleton binding, protein disruption, apoptosis and glycolysis proteins displayed a 
significantly changed expression in OA chondrocytes. Overall, the results suggested the 
deregulated production in OA cartilage of proteins pertaining to key cellular processes 
essential for the proper functioning of the chondrocytes, which may have direct effects on 
OA cartilage biology. 
A similar approach was also carried out to study the differential proteome of bone marrow 
MSCs (BM-MSCs) (Rollin, 2008b) from patients with OA vs. MSCs control, obtained from 
patients with hip fracture without OA signs. In this study we demonstrated the existence of 
specific alterations in the proteome content of bone marrow MSCs from patients with OA. 
Once classified into different groups, according to their biological function, the majority of 
proteins that changed at least 1.5-fold, belonged to the metabolic enzymes, 
cytoskeleton/motility and transport categories. Markedly, most proteins related to 
cytoskeleton/motility were down-regulated in MSCs from OA patients. Considering 
previous evidences supporting that MSCs can home to some tissues, particularly when 
injured or inflamed, the mechanisms underlying migratory capacity, as a key event for 
tissue repair by MSCs, were also studied in vitro using PDGF as chemoattractant. Our 
results demonstrated a significant increase in the motility of MSC of OA patients. Together 
with the differential expression of metabolic and cytoskeleton proteins we concluded that an 
activation of OA BM-MSCs occurs in response to chemotactic signals sent by the altered 
subchondral bone in an attempt to heal damaged tissues.  
3.2 Gene expression alterations in bone marrow MSCs in osteoarthritis 
Our previous experimental data obtained in MSCs proteomic studies indicate an 
increased migratory capacity of BM-MSCs to the damaged tissues, likely to initiate 
and/or enhance the wound repair process. In this context, it is known that transforming 
growth factor-β (TGF-β) plays an important role in directing the cell fate choices in 
mesenchymal cells (Roelen, 2003). TGF-β induces the chondrogenic differentiation of MSC 
in the presence of dexamethasone or 3-dimensional cell aggregates (Mackay, 1998) and 
may act in conjunction with other microenvironmental factors on MSC differentiation. To 
assess the importance of TGF-β expression in MSCs from OA we comparatively studied 
by quantitative real-time PCR the expression of genes encoding the total TGF-β and those 
of the 3 isoforms of TGF-β (1, 2, 3) and TGF-β receptors (TBR-I, TBR-II, TBR-III) in 
primary cultures of BM-MSCs from patients with end stage OA and healthy control 
subjects (Rollin, 2008a). Our results showed that only TGF-β1 isoform was significantly 
increased in MSCs from OA. In addition, we also described an increased expression of 
TBR-II and TBR-III genes, but not of TBR-I in MSCs from OA. A possible explanation for 
this upregulated TGF-β upregulation in MSCs could be related to an stimulatory effect on 
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mesenchymal cell proliferation in bone marrow allowing their expansion in response to 
the bone and cartilage damage characteristic of this disease. 
More recently, another experimental approach was carried out by our group based on the 
comprehensive study of gene expression of MSCs using a DNA microarray expression 
analysis (Lamas, 2010). Gene expression profiles of MSCs from OA patients were compared 
to those of MSCs from healthy individuals. After integration of expression profiles into 
functional categories, by means of a gene ontology (GO)-based statistical analysis using 
GeneCodis 2.0 (Carmona-Saez, 2007), seventy-five genes from a list of 532 provided for 
comparison did not show annotations. The remaining 457 genes were grouped into different 
GO categories based on the subcellular location and functionality (Figure 6). Functional 
categories showing a major number of genes with downregulated expression in OA-MSCs  
 
Fig. 6. Differential expression of genes in osteoarthritis mesenchymal stem cells (OA-MSCs) 
according to gene ontology (GO) categories.  
The X-axis represents individual genes classified according to the gene ontology (GO) slim 
categories provided by the GeneCodis2 (Carmona-Saez, 2007) analysis. The Y-axis 
represents the fold variation in expression of OA-MSCs compared to control subjects 
(p<0.05). Only genes expressing at least twofold differences in expression were considered. 
A: Multicellular organismal development; B: Signal transduction; C: Cell differentiation; D: 
Cell-cell signaling; E: Cell proliferation; F: Metabolic Process; G: Carbohydrate Metabolic 
Process; H: Anatomical structure morphogenesis; I: Cytoskeleton organization; J: Response 
to stress; K: Cellular component organization; L: Response to external stimulus; M: Growth 
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were signal transduction, development and cell differentiation, which in turn are key 
functions in pluripotential cells. Based on the function of the proteins encoded by these 
genes, our results suggested that MSCs from patients with OA have a diminished 
differentiation and regenerative potentials that limit ther ability to generate a functional 
lineage of cells involved in musculoskeletal tissue homeostasis. 
Overall, in this study we provided a reference dataset of genes related to essential functions for 
the normal biology of MSCs that become altered in OA (Figure 4). We also described for the 
first time an association between the COL10A1 gene and OA susceptibility suggesting that 
underlying biological changes which occur during OA disease might be related, at least in 
part, to defects in the ECM and the formation of subchondral bone, an essential structure for 
providing joint stability. Moreover, in this work we also demonstrated that the expression of 
multiple genes related to the wnt pathway were downregulated in OA patients. 
3.3 Animal models in regenerative medicine (tendon repair) 
Chronic degeneration is the most frequent cause for lesions of the rotator cuff, a set of four 
tendons connecting the scapula with the humeral head in shoulder. The most affected 
tendon of the cuff, frequently affected by tears, is the supraspinatus tendon. These lesions 
are increased in aged patients who frequently need reconstructive surgery. Surgical 
methods are often unsatisfactory due to inefficient recovery. In this context, MSC-based 
regenerative medicine offers a hopeful alternative for this type of treatment. In this sense, 
our group is performing several studies focused on the evaluation of the effectiveness of 
recovery after treatments consisting in surgical implantations of MSCs alone or in 
combination with a commercial membrane of type I collagen (OrthoadaptTM).  This strategy 
has been previously tested in in a model of acute and chronic injury in rats with promising 
results allowing us to conduct a clinical trial in humans that is currently under 
development. 
4. MSCs, conventional and other experimental treatments in OA 
Treatment of osteoarthritis includes a combination of pharmacological and non-
pharmacological measures aimed at relieving pain and the improvement of joint function. 
Initial treatment is dependent on the extent of the disease, age of patients and the joints 
affected, in descending order of frequency: Hip, Knee, Foot and Ankle. In mild cases, 
treatment begins by the use of simple analgesics (eg. paracetamol), (Nonsteroidal anti-
inflammatory drugs) NSAIDs (eg. ibuprofen and naproxen) or intermittent intra-articular 
administration (infiltration) of corticosteroids. However, although the symptoms and pain 
can be partially alleviated, adverse effects associated with conventional drug therapy is not 
recommended for long time periods. Moreover, treatment is often accompanied by non-
pharmacological treatments, these include patient education and physical exercises to 
restore joint movement and to increase muscle strength, reduction of weight on painful 
joints. When joints are severely damaged treatment may require surgery. The most common 
surgical treatments are arthroscopic surgery, to trim damaged cartilage. Osteotomy, to 
change the alignment of a bone to relieve stress on the bone or joint. Arthrodesis or surgical 
fusion of bones, usually in the spine and the total or partial arthroplasty to replace the 
damaged joint with an artificial one. 
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Halfway between drug therapy and joint replacement surgery, several arthroscopic 
strategies combined with cell therapies have been developed for the treatment of cartilage 
injuries. The techniques used and the results obtained greatly vary depending on the size of 
the lesion. For smaller and medium sized cartilage defects, autologous osteochondral 
cylinder transfer or mosaicplasty has been widely used but its efficacy is limited by donor 
site morbidity and the poor integration of implants.  
Techniques of cell therapy in OA were initially based on the stimulation of bone marrow by 
drilling, microfracture and abrasive chondroplasty to promote better access of pluripotential 
stem cells from subchondral vascular area, to the site of injury (Steinwachs, 2008; Chen, 
2011). Although the microfracture has achieved good results in terms of functionality and 
reduction of pain, several limitations such as chondral defect size and age of the patient are 
major constraints. These methods only provide a partial filling of the defect with 
fibrocartilage without the characteristics of hyaline cartilage. More recently improvements 
of these cell therapies have been made using the implantation of cultured autologous 
chondrocytes in the defect site (ACI) and a variation of this technique, using collagen Type 
III/I scaffolds, MACI (Matrix-induced autologous chondrocyte implantation) (Strauss, 2011; 
Ventura, 2011). MACI was developed to enable the treatment of larger defects when cell 
engaged procedures such as ACI cannot be used or it is not indicated. The results of the 
ongoing studies in chondrocyte implantation show better results in the formation of a 
hyaline-like cartilage with similar characteristics and durability than normal hyaline 
cartilage. In any case, the major drawbacks are that the chondrocytes harvesting require 
additional surgery and only a small number of chondrocytes can be isolated from the 
explants. In addition these cells lose their phenotypic characteristics in culture, limiting their 
application in extensive chondral defects, such as those produced in osteoarthritis. 
Otherwise, allograft transplantation is limited by donor availability.  
Table 1 shows a summary of the most common techniques used clinically and 
experimentally. However the number of combinations of treatment options with each 
strategy is unlimited and growing every day. A great number of studies involve animal 
models evaluating different scaffolds, number of cells and ambiental factors used, etc. 
However, given the complex variety of combinations, there are no well-conducted clinical 
trials in humans evaluating the efficacy of a particular method. 
In summary, regarding OA, advances in research for the development of new technologies 
in the management of cartilage defects is currently unresolved. Actually any treatment 
method provides consistent and acceptable long-term clinical results, and in particular for 
treatment of large chondral defects.  With evolving techniques, versatility, availability and 
differentiation potential of stem cells have become the hope to improve current treatments 
based on other more committed cells. Alone or in combination with different scaffold 
materials and environmental factors, including growth factors, signalling molecules and 
mechanical influence, these cells are exceptional candidates for engineer cartilage constructs 
in vitro. Several studies have shown an improvement in the quality of the new tissue 
formed, but its long-term efficacy and the mechanism by which it occurs are unknown. In 
this regard it has been postulated that the low intrinsic immunogenicity of MSCs along with 
its ability to reduce inflammation, are characteristics that determine the establishment of a 
less inflammatory environment that facilitates the repair. 
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Symptom Current approach Mode of action Advantages Disadvantages 
Initial stages (non surgical) 
Pain 
and 
Inflammation 
- Pharmacological 
treatment 
Analgesic  
Anti-inflammatory
Surgery not 
needed 
Adverse effects 
- Physical exercice 
Joint structures 
reinforcement 
Not 
recommended 
in some cases 
- Educational Prevention none 
Structural damage of joint cartílage (surgical methods) 
Small defects 
<2.5cm2 
- Subchondral drilling
- Microfracture 
- Abrasive 
chondroplasty 
Bone marrow 
stimulation 
Relatively 
inexpensive 
surgery 
 
 
Age of patients 
Inferior quality 
of neoformed 
tissue 
 
 
Structural damage of joint cartílage (trasplantation methods) 
 
Medium 
defects 
2.5 to 4 cm2 
- Osteochondral 
allografts 
 
 
- Autologous 
periosteal grafts 
 
 
- Autologous 
mosaicplasty 
Tissue 
trasplantation 
from autologous 
or allogeneic 
origin 
Age of donor 
eligible 
 
Relatively 
well suited 
for medium 
cartilage 
defects 
 
 
 
Availability of 
implants. 
 
Donor 
morbidity. 
 
Poor integration 
and maintenance 
of implant. 
 
- Autologous 
chondrocyte 
trasplantation (ACI) 
Cellular therapy 
using committed 
cell lineages 
Relatively 
well suited 
for medium 
cartilage 
defects 
 
 
Defect filling 
with hyaline 
cartilage in a 
short time 
 
 
Two sugeries  
needed 
 
Small number of 
chondrocyte 
availability 
 
Poor integration 
Do not show 
improvement 
over other 
conventional 
techniques 
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Symptom Current approach Mode of action Advantages Disadvantages 
- Matrix-induced 
autologous 
chondrocyte 
implantation (MACI)
Better early 
results 
 
Medium and 
long-term 
results not 
available  
 
Expensive 
 
Mesenchymal Stem 
Cells (MSCs) 
Cellular therapy 
using stem cells  
Potential Expensive 
Large defects 
> 4 cm2 
Total arthroplasty Joint replacementt
Joint 
restoration 
Infections 
Expiration 
 
Table 1. Conventional and experimental treatments in OA. 
5. Conclusions and future perspectives 
The goal in regenerative medicine is based in a conceptually simple scheme: the 
development of new strategies to replace human cells or induce the regeneration of diseased 
or injured human tissues. Although during the last twenty years a considerable scientific 
progress has been done in this field, there are still many unanswered questions about key 
concepts concerning both tissue engineering and cell therapy.  
Stem cells, in its two “flavours”: embryonic and adult stem cells are the basis of regenerative 
medicine; however, biological differences between adult and embryonic stem cells and 
among adult stem cells found in different tissues is an important aspect which implication 
for therapeutic uses is not resolved. From the point of view of their clinical application, the 
source of the cells is of extreme importance. In the case of autologous cells that are not 
rejected by the patient’s immune system their application is potentially safer than in 
allogeneic cells and more suitable for permanent tissue replacement. However, and for 
example, in cases where the recipient suffers from a genetic disorder, their application 
would be inappropriate. Future efforts should be done to minimise rejection, and to favour 
the banking and use of allogeneic adult cells. Among adult stem cells, the MSCs are of 
paramount importance for the treatment of several rheumatic diseases. Besides their 
plasticity and regenerative potential they show immunosuppressive and antiinflammatory 
characteristics in vitro and proven in preclinical and clinical studies. 
Future studies will need to focus on the particular cell biology of MSCs including the 
biochemical signal transduction pathways involved in maintaining and enhancing 
chondrogenic differentiation, but also in the mechanisms implicated in immunomodulation. 
Other important aspects that need further research include the evaluation of safety and 
efficacy of local or systemic modes of admistration of MSCs; the mechanisms of cell to cell 
communication, such as microvesicles transporting RNAs, cytokines, etc.; the behaviour of 
MSCs in different niches; the design of specialised engineered scaffolds, to enable the 
efficient repair of a variety of tissues; and finally, the implementation and use of genetic 
reprogramming strategies.  
www.intechopen.com
 
Therapeutic Potential of MSCs in Musculoskeletal Diseases (Osteoarthritis) 
 
277 
6. Acknowledgments 
Special thanks to Peter Clarke and his disinterested revision and editing of the manuscript 
and to Dr. Emilio Camafeita for providing some of the representations included.  
This work was supported by a research grant from Roche Farma S.A. and was also partially 
supported by the RETICS Program, RD08/0075 (RIER) from Instituto de Salud Carlos III. 
7. References 
Aggarwal S; Pittenger MF. (2005). Human mesenchymal stem cells modulate allogeneic 
immune cell responses. Blood, Vol. 105, No. 4, pp. (1815-1822), ISSN:0006-4971 
Alban A; David SO; Bjorkesten L et al. (2003). A novel experimental design for comparative 
two-dimensional gel analysis: two-dimensional difference gel electrophoresis 
incorporating a pooled internal standard. Proteomics, Vol. 3, No. 1, pp. (36-44), ISSN 
1615-9853 
Alvarez-Dolado M. (2007). Cell fusion: biological perspectives and potential for regenerative 
medicine. Front biosci, Vol. 12, pp. (1-12) , ISSN 1093-4715 
Aspden RM. (2008). Osteoarthritis: a problem of growth not decay? Rheumatology (Oxford), 
Vol. 47, No. 10, pp. (1452-1460) , ISSN 1462-0332 
Bansback NJ; Regier DA; Ara R et al. (2005). An overview of economic evaluations for drugs 
used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists. 
Drugs, Vol. 65, No. 4, pp. (473-496) , ISSN 0012-6667 
Bianco P; Riminucci M; Gronthos S et al. (2001). Bone marrow stromal stem cells: nature, 
biology, and potential applications. Stem Cells, Vol. 19, No. 3, pp. (180-192) , ISSN 
1066-5099 
Brandt KD; Radin EL; Dieppe PA et al. (2006). Yet more evidence that osteoarthritis is not a 
cartilage disease. Ann Rheum Dis, Vol. 65, No. 10, pp. (1261-1264) , ISSN 0003-4967 
Bruder SP; Jaiswal N; Haynesworth SE. (1997). Growth kinetics, self-renewal, and the 
osteogenic potential of purified human mesenchymal stem cells during extensive 
subcultivation and following cryopreservation. J Cell Biochem, Vol. 64, No. 2, pp. 
(278-294) , ISSN 0730-2312 
Camafeita E; Lamas JR; Calvo E et al. (2009). Proteomics: New insights into rheumatic 
diseases. Proteomics Clinical Applications, Vol. 3, No. 2, pp. (226-241) , ISSN 1862-
8346 
Caplan AI. (2000). Mesenchymal stem cells and gene therapy. Clin Orthop Relat Res, Vol. No. 
(379 Suppl), pp. (S67-70) , ISSN 0009-921X 
Caplan AI. (2007). Adult mesenchymal stem cells for tissue engineering versus regenerative 
medicine. J Cell Physiol, Vol. 213, No. 2, pp. (341-347), ISSN 0021-9541 
Carmona-Saez P; Chagoyen M; Tirado F et al. (2007). GENECODIS: a web-based tool for 
finding significant concurrent annotations in gene lists. Genome Biol, Vol. 8, No. 1, 
pp. (R3), ISSN 1465-6914 
Chanda D; Kumar S; Ponnazhagan S. (2010). Therapeutic potential of adult bone marrow-
derived mesenchymal stem cells in diseases of the skeleton. J Cell Biochem, Vol. 111, 
No. 2, pp. (249-257) ISSN 1097-4644 
www.intechopen.com
 
Tissue Regeneration – From Basic Biology to Clinical Application 
 
278 
Chang CH; Kuo TF; Lin FH et al. (2011). Tissue engineering-based cartilage repair with 
mesenchymal stem cells in a porcine model. J Orthop Res, ISSN 1554-527X 
Chen H, Hoemann CD, Sun J, Chevrier A, McKee MD, Shive MS, et al. Depth of 
subchondral perforation influences the outcome of bone marrow stimulation 
cartilage repair. J Orthop Res, Vol. 29, No. 8, (Aug), pp. (1178-1184) ISSN 1554-527X 
Chen L; Tredget EE; Wu PY et al. (2008). Paracrine factors of mesenchymal stem cells recruit 
macrophages and endothelial lineage cells and enhance wound healing. PLoS One, 
Vol. 3, No. 4, pp. (e1886), ISSN 1932-6203 
Chivu M; Dima SO; Stancu CI et al. (2009). In vitro hepatic differentiation of human bone 
marrow mesenchymal stem cells under differential exposure to liver-specific 
factors. Transl Res, Vol. 154, No. 3, pp. (122-132), ISSN 1931-5244 
Conget PA; Minguell JJ. (1999). Phenotypical and functional properties of human bone 
marrow mesenchymal progenitor cells. J Cell Physiol, Vol. 181, No. 1, pp. (67-73), 
ISSN 0021-9541 
Day TF; Guo X; Garrett-Beal L et al. (2005). Wnt/beta-catenin signaling in mesenchymal 
progenitors controls osteoblast and chondrocyte differentiation during vertebrate 
skeletogenesis. Dev Cell, Vol. (8), No. (5), pp. (739-750), ISSN 1534-5807  
Dennis JE; Merriam A; Awadallah A et al. (1999). A quadripotential mesenchymal 
progenitor cell isolated from the marrow of an adult mouse. J Bone Miner Res, Vol. 
14, No. (5, pp. (700-709), ISSN 0884-0431 
Gaur T; Lengner CJ; Hovhannisyan H et al. (2005). Canonical WNT signaling promotes 
osteogenesis by directly stimulating Runx2 gene expression. J Biol Chem, Vol. 280, 
No. 39, pp. (33132-33140), ISSN 0021-9258 
Gerdoni E; Gallo B; Casazza S et al. (2007). Mesenchymal stem cells effectively modulate 
pathogenic immune response in experimental autoimmune encephalomyelitis. Ann 
Neurol, Vol. 61, No. 3, pp. (219-227) , ISSN 0364-5134 
Gupta N; Su X; Popov B et al. (2007). Intrapulmonary delivery of bone marrow-derived 
mesenchymal stem cells improves survival and attenuates endotoxin-induced acute 
lung injury in mice. J Immunol, Vol. 179, No. 3, pp. (1855-1863), ISSN 0022-1767 
Hill TP; Spater D; Taketo MM et al. (2005). Canonical Wnt/beta-catenin signaling prevents 
osteoblasts from differentiating into chondrocytes. Dev Cell, Vol. 8, No. 5, pp. (727-
738), ISSN 1534-5807 
Karussis D; Kassis I; Kurkalli BG et al. (2008). Immunomodulation and neuroprotection with 
mesenchymal bone marrow stem cells (MSCs): a proposed treatment for multiple 
sclerosis and other neuroimmunological/neurodegenerative diseases. J Neurol Sci, 
Vol. 265, No. 1-2, pp. (131-135), ISSN 0022-510X 
Lamas JR; Rodriguez-Rodriguez L; Vigo AG et al. (2010). Large-scale gene expression in 
bone marrow mesenchymal stem cells: a putative role for COL10A1 in 
osteoarthritis. Ann Rheum Dis, Vol. 69, No. 10, pp. (1880-1885), ISSN 1468-2060 
Lane Smith R; Trindade MC; Ikenoue T et al. (2000). Effects of shear stress on articular 
chondrocyte metabolism. Biorheology, Vol. 37, No. 1-2, pp. (95-107), ISSN 0006-355X 
Laupattarakasem W; Laopaiboon M; Laupattarakasem P et al. (2008). Arthroscopic 
debridement for knee osteoarthritis. Cochrane Database Syst Rev, Vol. No. (1), pp. 
(CD005118), ISSN 1469-493X 
www.intechopen.com
 
Therapeutic Potential of MSCs in Musculoskeletal Diseases (Osteoarthritis) 
 
279 
Le Blanc K; Rasmusson I; Sundberg B et al. (2004). Treatment of severe acute graft-versus-
host disease with third party haploidentical mesenchymal stem cells. Lancet, Vol. 
363, No. 9419, pp. (1439-1441), ISSN 1474-547X 
Le Blanc K; Ringden O. (2007). Immunomodulation by mesenchymal stem cells and clinical 
experience. J Intern Med, Vol. 262, No. 5, pp. (509-525), ISSN 0954-6820 
Lee RH; Seo MJ; Reger RL et al. (2006). Multipotent stromal cells from human marrow home 
to and promote repair of pancreatic islets and renal glomeruli in diabetic 
NOD/scid mice. Proc Natl Acad Sci U S A, Vol. 103, No. 46, pp. (17438-17443), ISSN 
0027-8424 
Li WJ; Tuli R; Okafor C et al. (2005). A three-dimensional nanofibrous scaffold for cartilage 
tissue engineering using human mesenchymal stem cells. Biomaterials, Vol. 26, No. 
6, pp. (599-609), ISSN 0142-9612 
Licatalosi DD; Darnell RB. (2010). RNA processing and its regulation: global insights into 
biological networks. Nat Rev Genet, Vol. 11, No. 1, pp. (75-87), ISSN 1471-0064 
Lisignoli G; Cristino S; Piacentini A et al. (2005). Cellular and molecular events during 
chondrogenesis of human mesenchymal stromal cells grown in a three-dimensional 
hyaluronan based scaffold. Biomaterials, Vol. 26, No. 28, pp. (5677-5686), ISSN 0142-
9612 
Loza E; Abasolo L; Jover JA et al. (2008). Burden of disease across chronic diseases: a health 
survey that measured prevalence, function, and quality of life. J Rheumatol, Vol. 35, 
No. 1, pp. (159-165), ISSN 0315-162X 
Mackay AM; Beck SC; Murphy JM et al. (1998). Chondrogenic differentiation of cultured 
human mesenchymal stem cells from marrow. Tissue Eng, Vol. 4, No. 4, pp. (415-
428), ISSN 1076-3279 
Manners PJ. (2003). Epidemiology of the rheumatic diseases of childhood. Curr Rheumatol 
Rep, Vol. 5, No. 6, pp. (453-457), ISSN 1523-3774 
Mariller MM; Santos-Eggimann B. (2005). The prevalence of rheumatic diseases in the 
elderly in developed countries and its evolution over time. Soz Praventivmed, Vol. 
50, No. 1, pp. (45-51), ISSN 0303-8408 
Moretti P; Hatlapatka T; Marten D et al. (2010). Mesenchymal stromal cells derived from 
human umbilical cord tissues: primitive cells with potential for clinical and tissue 
engineering applications. Adv Biochem Eng Biotechnol, Vol. 123, No. pp. (29-54), 
ISSN 1616-8542 
Munoz JR; Stoutenger BR; Robinson AP et al. (2005). Human stem/progenitor cells from 
bone marrow promote neurogenesis of endogenous neural stem cells in the 
hippocampus of mice. Proc Natl Acad Sci U S A, Vol. 102, No. 50, pp. (18171-18176), 
ISSN 0027-8424 
Necas A; Planka L; Srnec R et al. (2010). Quality of newly formed cartilaginous tissue in 
defects of articular surface after transplantation of mesenchymal stem cells in a 
composite scaffold based on collagen I with chitosan micro- and nanofibres. 
Physiological research / Academia Scientiarum Bohemoslovaca, Vol. 59, No. 4, pp. (605-
614), ISSN 0862-8408 
www.intechopen.com
 
Tissue Regeneration – From Basic Biology to Clinical Application 
 
280 
Ortiz LA; Dutreil M; Fattman C et al. (2007). Interleukin 1 receptor antagonist mediates the 
antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung 
injury. Proc Natl Acad Sci U S A, Vol. 104, No. 26, pp. (11002-11007), ISSN 1091-6490 
Pereira RF; Halford KW; O'Hara MD et al. (1995). Cultured adherent cells from marrow can 
serve as long-lasting precursor cells for bone, cartilage, and lung in irradiated mice. 
Proc Natl Acad Sci U S A, Vol. 92, No. 11, pp. (4857-4861), ISSN 0027-8424 
Pittenger MF; Mackay AM; Beck SC et al. (1999). Multilineage potential of adult human 
mesenchymal stem cells. Science, Vol. 284, No. 5411, pp. (143-147), ISSN 0036-8075 
Quintana L; zur Nieden NI; Semino CE. (2009). Morphogenetic and regulatory mechanisms 
during developmental chondrogenesis: new paradigms for cartilage tissue 
engineering. Tissue Eng Part B Rev, Vol. 15, No. 1, pp. (29-41), ISSN 1937-3368 
Reiser J; Zhang XY; Hemenway CS et al. (2005). Potential of mesenchymal stem cells in gene 
therapy approaches for inherited and acquired diseases. Expert Opin Biol Ther, Vol. 
5, No. 12, pp. (1571-1584), ISSN 1744-7682 
Remy-Martin JP; Marandin A; Challier B et al. (1999). Vascular smooth muscle 
differentiation of murine stroma: a sequential model. Exp Hematol, Vol. 27, No. 12, 
pp. (1782-1795), ISSN 0301-472X 
Ren G; Zhang L; Zhao X et al. (2008). Mesenchymal stem cell-mediated immunosuppression 
occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell, Vol. 2, 
No. 2, pp. (141-150), ISSN 1875-9777 
Roelen BA; Dijke P. (2003). Controlling mesenchymal stem cell differentiation by TGFBeta 
family members. J Orthop Sci, Vol. 8, No. 5, pp. (740-748), ISSN 0949-2658 
Rollin R; Alvarez-Lafuente R; Marco F et al. (2008a). Abnormal transforming growth factor-
beta expression in mesenchymal stem cells from patients with osteoarthritis. J 
Rheumatol, Vol. 35, No. 5, pp. (904-906), ISSN 0315-162X 
Rollin R; Marco F; Camafeita E et al. (2008b). Differential proteome of bone marrow 
mesenchymal stem cells from osteoarthritis patients. Osteoarthritis Cartilage, Vol. 16, 
No. 8, pp. (929-935), ISSN 1063-4584 
Rollin R; Tornero P; Marco F et al. (2008c). Differential Proteome of Articular Chondrocytes 
From Patients with Osteoarthritis. J Proteomics Bioinformatics, Vol. 1, No. pp. (267-
280), ISSN 1063-4584 
Romanov YA; Darevskaya AN; Merzlikina NV et al. (2005). Mesenchymal stem cells from 
human bone marrow and adipose tissue: isolation, characterization, and 
differentiation potentialities. Bull Exp Biol Med, Vol. 140, No. 1, pp. (138-143), ISSN 
0007-4888 
Spaeth E; Klopp A; Dembinski J et al. (2008). Inflammation and tumor microenvironments: 
defining the migratory itinerary of mesenchymal stem cells. Gene Ther, Vol. 15, No. 
10, pp. (730-738), ISSN 1476-5462 
Spahn G; Schiele R; Hofmann GO et al. (2011). [The Prevalence of Radiological 
Osteoarthritis in Relation to Age, Gender, Birth-Year Cohort, and Ethnic Origins.]. 
Z Orthop Unfall, Vol. 149, No. 2, pp. (145-152), ISSN 1864-6743 
Spees JL; Olson SD; Whitney MJ et al. (2006). Mitochondrial transfer between cells can 
rescue aerobic respiration. Proc Natl Acad Sci U S A, Vol. 103, No. 5, pp. (1283-1288), 
ISSN 0027-8424 
www.intechopen.com
 
Therapeutic Potential of MSCs in Musculoskeletal Diseases (Osteoarthritis) 
 
281 
Spees JL; Olson SD; Ylostalo J et al. (2003). Differentiation, cell fusion, and nuclear fusion 
during ex vivo repair of epithelium by human adult stem cells from bone marrow 
stroma. Proc Natl Acad Sci U S A, Vol. 100, No. 5, pp. (2397-2402), ISSN 0027-8424 
Steinwachs M. (2009). New technique for cell-seeded collagen-matrix-supported autologous 
chondrocyte transplantation. Arthroscopy, Vol. 25 No.2, pp. (208-211). 
Strauss, E. J. et al. Fonseca, L. E. et al. Shah, M. R., et al. (2011). Management of focal 
cartilage defects in the knee - Is ACI the answer? Bull NYU Hosp Jt Dis, Vol. 69, No. 
1, pp. (63-72). ISSN 1936-9727 
Stults JT; Arnott D. (2005). Proteomics. Methods Enzymol, Vol. 402, pp. (245-289), ISSN 0076-
6879 
Suzuki K; Sun R; Origuchi M et al. (2011). Mesenchymal Stromal Cells Promote Tumor 
Growth Through the Enhancement of Neovascularization. Mol Med, ISSN 1528-
3658 
Thorpe SD; Buckley CT; Vinardell T et al. (2010). The response of bone marrow-derived 
mesenchymal stem cells to dynamic compression following TGF-beta3 induced 
chondrogenic differentiation. Ann Biomed Eng, Vol. 38, No. 9, pp. (2896-2909), ISSN 
1521-6047 
Tian LL; Yue W; Zhu F et al. (2011). Human mesenchymal stem cells play a dual role on 
tumor cell growth in vitro and in vivo. J Cell Physiol, Vol. 226, No. 7, pp. (1860-
1867), ISSN 1097-4652 
Unlu M; Morgan ME; Minden JS. (1997). Difference gel electrophoresis: a single gel method 
for detecting changes in protein extracts. Electrophoresis, Vol. 18, No. 11, pp. (2071-
2077), ISSN 0173-0835 
Vanarsa K; Mohan C. (2010). Proteomics in rheumatology: the dawn of a new era. F1000 Med 
Rep, Vol. 2, No. pp. (87), ISSN 1757-5931 
Ventura, A. et al. Memeo, A. et al. Borgo, E., et al. (2011). Repair of osteochondral lesions in 
the knee by chondrocyte implantation using the MACI(®) technique. Knee Surg 
Sports Traumatol Arthrosc, Vol. No. (Jun 17), pp. 
Viswanathan S; Unlu M; Minden JS. (2006). Two-dimensional difference gel electrophoresis. 
Nat Protoc, Vol. 1, No. 3, pp. (1351-1358), ISSN 1750-2799 
Worthington J. (2005). Investigating the genetic basis of susceptibility to rheumatoid 
arthritis. J Autoimmun, Vol. (25 Suppl), No. pp. (16-20), ISSN 0896-8411 
Zavan B; Giorgi C; Bagnara GP et al. (2007). Osteogenic and chondrogenic differentiation: 
comparison of human and rat bone marrow mesenchymal stem cells cultured into 
polymeric scaffolds. Eur J Histochem, Vol. (51 Suppl 1), No. pp. (1-8), ISSN 1121-
760X 
Zhou XZ; Leung VY; Dong QR et al. (2008). Mesenchymal stem cell-based repair of articular 
cartilage with polyglycolic acid-hydroxyapatite biphasic scaffold. The International 
journal of artificial organs, Vol. 31, No. 6, pp. (480-489), ISSN 0391-3988 
Zhu M; Tang D; Wu Q et al. (2009). Activation of beta-catenin signaling in articular 
chondrocytes leads to osteoarthritis-like phenotype in adult beta-catenin 
conditional activation mice. J Bone Miner Res, Vol. 24, No. 1, pp. (12-21), ISSN 1523-
4681 
www.intechopen.com
 
Tissue Regeneration – From Basic Biology to Clinical Application 
 
282 
Zscharnack M; Hepp P; Richter R et al. (2010). Repair of chronic osteochondral defects using 
predifferentiated mesenchymal stem cells in an ovine model. Am J Sports Med, Vol. 
38, No. 9, pp. (1857-1869), ISSN 1552-3365 
www.intechopen.com
Tissue Regeneration - From Basic Biology to Clinical Application
Edited by Prof. Jamie Davies
ISBN 978-953-51-0387-5
Hard cover, 512 pages
Publisher InTech
Published online 30, March, 2012
Published in print edition March, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
When most types of human tissue are damaged, they repair themselves by forming a scar - a mechanically
strong 'patch' that restores structural integrity to the tissue without restoring physiological function. Much
better, for a patient, would be like-for-like replacement of damaged tissue with something functionally
equivalent: there is currently an intense international research effort focused on this goal. This timely book
addresses key topics in tissue regeneration in a sequence of linked chapters, each written by world experts;
understanding normal healing; sources of, and methods of using, stem cells; construction and use of scaffolds;
and modelling and assessment of regeneration. The book is intended for an audience consisting of advanced
students, and research and medical professionals.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
José Ramón Lamas, Pilar Tornero-Esteban and Benjamín Fernández-Gutiérrez (2012). Therapeutic Potential
of MSCs in Musculoskeletal Diseases (Osteoarthritis), Tissue Regeneration - From Basic Biology to Clinical
Application, Prof. Jamie Davies (Ed.), ISBN: 978-953-51-0387-5, InTech, Available from:
http://www.intechopen.com/books/tissue-regeneration-from-basic-biology-to-clinical-application/therapeutic-
potential-of-mscs-in-musculoskeletal-diseases-osteoarthritis-
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
